PT -期刊文章盟罗莎Cortese AU -丽丝Magnollay AU - Floriana De旧金山盟卡门病重AU -弗兰普拉多盟Sebastien Ourselin盟腻过Yiannakas盟David Miller -伊莎贝拉劳拉·西蒙盟盟——Tarek Yousry AU -奥尔加Ciccarelli TI -中央静脉标志在瑞士3 t MRI多发性硬化症有别于Neuromyelitis视(P4.147) DP - 2016年4月05 TA -神经病学PG - P4.147 VI - 86 IP - 16补充4099 - //www.ez-admanager.com/content/86/16_Supplement/P4.147.short 4100 - //www.ez-admanager.com/content/86/16_Supplement首页/P4.147.full所以Neurology2016 4月05;86 AB -目的:评估中央静脉的歧视性的价值符号(CVS) susceptibility-weighted成像(瑞士)获得临床扫描仪(3 t)视neuromyelitis谱系障碍(NMOSD)和多发性硬化症(MS)。背景:这将是有用的识别脑磁共振成像(MRI)特征有助于区分NMOSD和前一个女士在7 t的研究已经表明,中央静脉NMOSD病变并不常见,但它是典型的方法:女士18 NMOSD (14 f,意味着(SD)年龄52±11岁,除了两个AQP4抗体阳性)和16个复发汇款MS患者(12 f,意味着(SD)年龄41[±9]岁)在3 t进行扫描。白质病变(WM)首次发现在T2图像分为infratentorial,室旁或皮层下。随后,的存在至少一个静脉,描绘成一个黑暗线追逐通过病变或一个点跟踪连续切片,在瑞士进行评估。逻辑回归模型被用来评估之间的联系CVS和类型的疾病(女士比NMOSD),在调整了年龄、性别、和疾病持续时间。结果:共有719 WM病变被认为在16个16医学患者;177年16 18 NMOSD病变检测的病人。CVS在575年确定病变女士(80 [percnt]),和67年(38 [percnt]) NMOSD病变。在两组,CVS是最常见的在室周的病变(女士:65 (percnt); NMOSD:63[percnt]), followed by subcortical (MS:25[percnt]; NMOSD:14[percnt]) and infratentorial lesions (MS:10[percnt]; NMOSD:13[percnt]). The presence of the CVS was strongly associated with this WM lesion belonging to a MS patient (OR=6.49, 95[percnt] CI 3.69, 11.69, p<0.001). CONCLUSIONS: The CVS on SWI is typical of MS patients and can improve the differential diagnosis between MS from NMOSD when using a clinical MRI scanner.Disclosure: Dr. Cortese has nothing to disclose. Dr. Magnollay has nothing to disclose. Dr. De Angelis has nothing to disclose. Dr. Tur Gomez has received personal compensation for activities with TEVA Pharmaceuticals, Ismar Healthcare, Serono Symposia International Foundation as a consultant. Dr. Prados has nothing to disclose. Dr. Ourselin has nothing to disclose. Dr. Yiannakas has nothing to disclose. Dr. Distaso has nothing to disclose. Dr. Miller has nothing to disclose. Dr. Yousry has received research support from Biogen Idec, British Heart Foundation, GlaxoSmithKline, Medical Research Council, MS Society of Great Britain and Northern Ireland, and NIHR Comprehensive. Dr. Ciccarelli has received personal compensation for activities with Novartis, Biogen and GE as a consultant.Tuesday, April 19 2016, 8:30 am-7:00 pm